Correlation between the blood membrane-bound progesterone level and clinical application in patients with breast cancer

doi:10.3969/j.issn.1006-7795.2018.04.002

Abstract

Abstract: Objective To detect the PGRMC1 level in blood samples from breast cancer patients and evaluate the clinical value in diagnosis of breast cancer. Methods The whole blood PGRMC1 levels were measured by enzyme linked immunosorbent assay (ELISA) and the serum CA125, CEA and CA153 levels were measured by chemiluminescent immunoassay (CLIA) technique in 90 breast cancer patients, 50 breast benign diseases and 30 healthy controls from September 2017 to January 2018. All participants signed informed consent voluntarily. Chi-square test was used for comparison between groups. Receiver operating characteristic (ROC) curve was used to evaluate diagnosis value of PGRMC1 in breast cancer. Results The level of PGRMC1 showed no difference between the benign group and the control group (P>0.05). The PGRMC1 levels showed significant difference in stage Ⅱ, Ⅲ and IV breast cancer group compared with the benign and the control groups (P<0.05 compared among groups). There was no significant change in the serum levels of CA125, CA153 and CEA in stage I and Ⅱ breast cancer patients with no statistically significant difference compared with the benign group and the control group (P>0.05). Compared with the benign group and the control group, the serum value of CA125, CA153 and CEA was significantly higher in stage Ⅲ and IV breast cancer group (P<0.05). In late stage, the area under the ROC curve (AUC) of PGRMC1, CA125, CA153 and CEA was 82.7%, 78.3%, 86.8% and 77.3% respectively. In early stage, the AUC of CA125, CA153 and CEA was below 60%, which showed nearly no significance in diagnosis for early breast cancer. While the AUC of PGRMC1 was 86.6%. The sensitivity of PGRMC1 was 94% and the specificity was 50%. Conclusion PGRMC1 was successfully detected with ELISA in blood samples from breast cancer patients and had applicable value for diagnosis in both early and late phase of breast cancer. There is a possibility that PGRMC1 may become a blood biomarker of early diagnosis and progression of breast cancer.

Key words: menopausal hormone therapy, progesterone receptor membrane component 1, breast cancer, enzyme-linked immuno sorbent assay, biomarker, receiver operating characteristic curve

CLC Number:

R711.77

Zhao Yue, Ruan Xiangyan, Zhang Quandong, Wang Husheng, Li Xue, Cai Guiju, Gu Muqing, Alfred O. Mueck. Correlation between the blood membrane-bound progesterone level and clinical application in patients with breast cancer[J]. Journal of Capital Medical University, 2018, 39(4): 486-493.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2018.04.002

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2018/V39/I4/486

References

[1] Fan L,Strasser-Weippl K, Li J J, et al. Breast cancer in China[J]. Lancet Oncol,2014,15(7):e279-e289.
[2] Prentice R L, LaCroix A Z, Chlebowski R T, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality:the women's health initiative randomized trials[J]. JAMA,2017,318(10):927-938.
[3] Cordina-Duverger E, Truong T, Anger A, et al. Risk of breast cancer by type of menopausal hormone therapy:a case-control study among post-menopausal women in France[J]. PLoS One,2013,8(11):e78016.
[4] Zhao Y, Ruan X, Wang H, et al. The presence of a membrane-bound progesterone receptor induces growth of breast cancer with norethisterone but not with progesterone:a xenograft model[J]. Maturitas, 2017,102:26-33.
[5] Ruan X, Zhao Y, Mueck A O, et al. Increased expression of progesterone receptor membrane component 1 is associated with aggressive phenotype and poor prognosis in ER-positive and negative breast cancer[J]. Menopause,2017,24(2):203-209.
[6] Zhao Y, Ruan X, Willibald M, et al. May progesterone receptor membrane component 1(PGRMC1) predict the risk of breast cancer?[J]. Gynecol Endocrinol,2016,32(1):58-60.
[7] Mohamed H, Russell I A, Stark R, et al. Progesterone receptor modulates ER-α action in breast cancer[J]. Nature,2015,523(7560):313-317.
[8] Clark N C, Friel A M, Pru C A, et al. Progesterone receptor membrane component 1 promotes survival of human breast cancer cells and the growth of xenograft tumors[J]. Cancer Biol Ther,2016,17(3):262-271.
[9] Böcker W. WHO classification of breast tumors and tumors of the female genital organs:pathology and genetics[J]. Verh Dtsch Ges Pathol,2002,86:116-119.
[10] Hari DM, Leung AM, Lee JH, et al. AJCC Cancer Staging Manual 7th edition criteria for colon cancer:do the complex modifications improve prognostic assessment?[J]. J Am Coll Surg,2013,217(2):181-190.
[11] Fan L, Zheng Y, Yu KD, et al. Breast cancer in a transitional society over 18 years:trends and present status in Shanghai, China[J]. Breast cancer Res Treat,2009,117(2):409-416.
[12] Hesari A, Golrokh Moghadam SA, Siasi A, et al. Tumor-derived exosomes:Potential biomarker or therapeutic target in breast cancer?[J]. J Cell Biochem,2018,119(6):4236-4240.
[13] Tang S, Wei L, Sun Y, et al. CA153 in breast secretions as a potential molecular marker for diagnosing breast cancer:a meta analysis[J]. PLoS One,2016,11(9):e0163030.
[14] Lu L, Li Y, Qi G, et al. Research progress in applying proteomics technology to explore early diagnosis biomarkers of breast cancer, lung cancer and ovariancancer[J]. Asian Pac J Cancer Prev,2014,15(20):8529-8538.
[15] Jafarpour-Sadegh F, Montazeri V, Adili A, et al. Effects of fresh yellow onion consumption on CEA, CA125 and hepatic enzymes in breast cancer patients:a double-blind randomized controlled clinical trial[J]. Asian Pac J Cancer Prev,2015,16(17):7517-7522.
[16] Zhang S J, Hu Y,Qian H L, et al. Expression and significance of ER, PR, VEGF, CA15-3, CA125 and CEA in judging the prognosis of breast cancer[J]. Asian Pac J Cancer Prev, 2013,14(6):3937-3940.
[17] Maccio G, Goussot V, Berriolo-Riedinger A, et al. Clinical value of CEA for detection of distant metastases in newly diagnosed breast cancer:comparison with CA15-3[J]. Ann Biol Clin:Paris,2017,75(4):431-441.
[18] Neubauer H, Ruan X, Mueck A O, et al. Possible role of PGRMC1 in breast cancer development[J]. Climacteric,2013,16(5):509-513.
[19] 王利娟, 阮祥燕, 赵越. PGRMC1在乳腺癌组织中的表达及其与临床病理特征的相关性[J]. 首都医科大学学报,2018,39(2):273-276.
[20] Ruan X, Neubauer H, Mueck A O, et al. Progestogens and membrane-initiated effects on the proliferation of human breast cancer cells[J]. Climacteric,2012,15(5):467-472.
[21] Wang X F, Wu Y H, Wang M S, et al. CEA, AFP, CA125, CA153 and CA199 in malignant pleural effusions predict the cause[J]. Asian Pac J Cancer Prev,2014,15(1):363-368.
[22] 牛爱军,张志强,孙晓明,等. 乳腺癌患者CEA、CA153临床应用价值探讨[J]. 实用医药杂志,2004,21(3):210-213.
[23] 杨志,杨贵生,李宁,等.全身骨显像联合CA15-3和CEA检测对乳腺癌骨转移的诊断价值[J].中华肿瘤防治杂志,2016,23(18):1229-1333.